FDA Determines Regulatory Review Period for INCRELEX Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for INCRELEX, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks, Department of Commerce.